Somaxon Pharmaceuticals
AboutProductsPartnersInvestorsNewsCareersContact

Overview
Press Releases
Stock Information
SEC Filings
Analyst Coverage
Webcasts/ IR Events
Investor FAQs
Request for Information


Join Our Mailing List

Please join our mailing list if you wish to receive news regarding Somaxon and its products.

Investors

Stock Quote

SOMX (Common Stock)
Last Trade:
0.32
Change:
- 0.02
Exchange:
NASDAQ
Volume:
230,300
3:59 PM ET  |   05/18/2012
Delayed at least 20 min., by eSignal.

Annual Reports

Somaxon Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the in-licensing, development and commercialization of proprietary branded pharmaceutical products for the treatment of diseases and disorders in the central nervous system therapeutic area. Somaxon's lead product candidate is Silenor® (doxepin) for the treatment of insomnia.

More Press Releases »   RSSLatest News

May 10, 2012
Somaxon Pharmaceuticals Reports First Quarter 2012 Financial Results

Apr 30, 2012
Somaxon Pharmaceuticals to Report First Quarter 2012 Results and Conduct Conference Call on Thursday, May 10


Home | Privacy Policy | Terms of Use | Site Map©2012 Somaxon Pharmaceuticals, Inc. All rights reserved. Silenor and Somaxon are registered trademarks of Somaxon Pharmaceuticals, Inc.